Sanofi’s latest fair value estimate has been nudged down from €106.26 to €105.20 as analysts factor in slightly softer revenue growth assumptions, even as the company’s overall risk profile remains ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

Sanofi (NASDAQ:SNY) is a French pharmaceutical firm that has been at the center of several analysts’ attention lately.

The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

A diagnosis of T-cell lymphoma after using Dupixent raises serious questions for patients and families. Many want clear ...

RegRegon Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent for treating moderate-to-severe chronic spontaneous urticaria in patients aged 12 and above who do ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best 52-week high stocks to buy right now. On December 3, TD Cowen’s ...

According to a report written by sister publication Dermatology Times (DT) in November, research from the 2025 Inflammatory Skin Disease Summit noted that itch can signal inflammation in the body.

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621.

Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in ...